The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Immuno-Oncology Market 2024 by Company, Regions, Type and Application, Forecast to 2028
Synopsis
The Immuno-Oncology market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our (Global Info Research) latest study, due to COVID-19 pandemic, the global Immuno-Oncology market size is estimated to be worth US$ 44910 million in 2021 and is forecast to a readjusted size of USD 114190 million by 2028 with a CAGR of 14.3% during review period. Hospitals accounting for % of the Immuno-Oncology global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While Immune Checkpoint Inhibitors segment is altered to a % CAGR between 2022 and 2028.
Global key companies of Immuno-Oncology include Bristol-Myers Squibb, Merck & Co., Inc., Roche AG, AstraZeneca, Plc, and Sanofi S.A., etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
Immuno-Oncology market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Immune Checkpoint Inhibitors
Cytokine-Based Immunotherapy
Cancer Vaccines
CAR-T Cell Therapy
Others
Market segment by Application, can be divided into
Hospitals
Drugstores
Others
Market segment by players, this report covers
Bristol-Myers Squibb
Merck & Co., Inc.
Roche AG
AstraZeneca, Plc
Sanofi S.A.
Dendreon Pharmaceuticals
Novartis
Gilead Sciences Inc.
Merck KGaA
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 12 chapters:
Chapter 1, to describe Immuno-Oncology product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top players of Immuno-Oncology, with revenue, gross margin and global market share of Immuno-Oncology from 2019 to 2022.
Chapter 3, the Immuno-Oncology competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with revenue and growth rate by Type, application, from 2017 to 2028.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2017 to 2022.and Immuno-Oncology market forecast, by regions, type and application, with revenue, from 2023 to 2028.
Chapter 11 and 12, to describe Immuno-Oncology research findings and conclusion, appendix and data source.
Geographical Area
Global
The Immuno-Oncology market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our (Global Info Research) latest study, due to COVID-19 pandemic, the global Immuno-Oncology market size is estimated to be worth US$ 44910 million in 2021 and is forecast to a readjusted size of USD 114190 million by 2028 with a CAGR of 14.3% during review period. Hospitals accounting for % of the Immuno-Oncology global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While Immune Checkpoint Inhibitors segment is altered to a % CAGR between 2022 and 2028.
Global key companies of Immuno-Oncology include Bristol-Myers Squibb, Merck & Co., Inc., Roche AG, AstraZeneca, Plc, and Sanofi S.A., etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
Immuno-Oncology market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Immune Checkpoint Inhibitors
Cytokine-Based Immunotherapy
Cancer Vaccines
CAR-T Cell Therapy
Others
Market segment by Application, can be divided into
Hospitals
Drugstores
Others
Market segment by players, this report covers
Bristol-Myers Squibb
Merck & Co., Inc.
Roche AG
AstraZeneca, Plc
Sanofi S.A.
Dendreon Pharmaceuticals
Novartis
Gilead Sciences Inc.
Merck KGaA
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 12 chapters:
Chapter 1, to describe Immuno-Oncology product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top players of Immuno-Oncology, with revenue, gross margin and global market share of Immuno-Oncology from 2019 to 2022.
Chapter 3, the Immuno-Oncology competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with revenue and growth rate by Type, application, from 2017 to 2028.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2017 to 2022.and Immuno-Oncology market forecast, by regions, type and application, with revenue, from 2023 to 2028.
Chapter 11 and 12, to describe Immuno-Oncology research findings and conclusion, appendix and data source.
Geographical Area
Global
Index1 Market Overview
1.1 Product Overview and Scope of Immuno-Oncology
1.2 Classification of Immuno-Oncology by Type
1.2.1 Overview: Global Immuno-Oncology Market Size by Type: 2017 Versus 2021 Versus 2028
1.2.2 Global Immuno-Oncology Revenue Market Share by Type in 2021
1.2.3 Immune Checkpoint Inhibitors
1.2.4 Cytokine-Based Immunotherapy
1.2.5 Cancer Vaccines
1.2.6 CAR-T Cell Therapy
1.2.7 Others
1.3 Global Immuno-Oncology Market by Application
1.3.1 Overview: Global Immuno-Oncology Market Size by Application: 2017 Versus 2021 Versus 2028
1.3.2 Hospitals
1.3.3 Drugstores
1.3.4 Others
1.4 Global Immuno-Oncology Market Size & Forecast
1.5 Global Immuno-Oncology Market Size and Forecast by Region
1.5.1 Global Immuno-Oncology Market Size by Region: 2017 VS 2021 VS 2028
1.5.2 Global Immuno-Oncology Market Size by Region, (2017-2022)
1.5.3 North America Immuno-Oncology Market Size and Prospect (2017-2028)
1.5.4 Europe Immuno-Oncology Market Size and Prospect (2017-2028)
1.5.5 Asia-Pacific Immuno-Oncology Market Size and Prospect (2017-2028)
1.5.6 South America Immuno-Oncology Market Size and Prospect (2017-2028)
1.5.7 Middle East and Africa Immuno-Oncology Market Size and Prospect (2017-2028)
1.6 Market Drivers, Restraints and Trends
1.6.1 Immuno-Oncology Market Drivers
1.6.2 Immuno-Oncology Market Restraints
1.6.3 Immuno-Oncology Trends Analysis
2 Company Profiles
2.1 Bristol-Myers Squibb
2.1.1 Bristol-Myers Squibb Details
2.1.2 Bristol-Myers Squibb Major Business
2.1.3 Bristol-Myers Squibb Immuno-Oncology Product and Solutions
2.1.4 Bristol-Myers Squibb Immuno-Oncology Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.1.5 Bristol-Myers Squibb Recent Developments and Future Plans
2.2 Merck & Co., Inc.
2.2.1 Merck & Co., Inc. Details
2.2.2 Merck & Co., Inc. Major Business
2.2.3 Merck & Co., Inc. Immuno-Oncology Product and Solutions
2.2.4 Merck & Co., Inc. Immuno-Oncology Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.2.5 Merck & Co., Inc. Recent Developments and Future Plans
2.3 Roche AG
2.3.1 Roche AG Details
2.3.2 Roche AG Major Business
2.3.3 Roche AG Immuno-Oncology Product and Solutions
2.3.4 Roche AG Immuno-Oncology Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.3.5 Roche AG Recent Developments and Future Plans
2.4 AstraZeneca, Plc
2.4.1 AstraZeneca, Plc Details
2.4.2 AstraZeneca, Plc Major Business
2.4.3 AstraZeneca, Plc Immuno-Oncology Product and Solutions
2.4.4 AstraZeneca, Plc Immuno-Oncology Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.4.5 AstraZeneca, Plc Recent Developments and Future Plans
2.5 Sanofi S.A.
2.5.1 Sanofi S.A. Details
2.5.2 Sanofi S.A. Major Business
2.5.3 Sanofi S.A. Immuno-Oncology Product and Solutions
2.5.4 Sanofi S.A. Immuno-Oncology Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.5.5 Sanofi S.A. Recent Developments and Future Plans
2.6 Dendreon Pharmaceuticals
2.6.1 Dendreon Pharmaceuticals Details
2.6.2 Dendreon Pharmaceuticals Major Business
2.6.3 Dendreon Pharmaceuticals Immuno-Oncology Product and Solutions
2.6.4 Dendreon Pharmaceuticals Immuno-Oncology Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.6.5 Dendreon Pharmaceuticals Recent Developments and Future Plans
2.7 Novartis
2.7.1 Novartis Details
2.7.2 Novartis Major Business
2.7.3 Novartis Immuno-Oncology Product and Solutions
2.7.4 Novartis Immuno-Oncology Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.7.5 Novartis Recent Developments and Future Plans
2.8 Gilead Sciences Inc.
2.8.1 Gilead Sciences Inc. Details
2.8.2 Gilead Sciences Inc. Major Business
2.8.3 Gilead Sciences Inc. Immuno-Oncology Product and Solutions
2.8.4 Gilead Sciences Inc. Immuno-Oncology Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.8.5 Gilead Sciences Inc. Recent Developments and Future Plans
2.9 Merck KGaA
2.9.1 Merck KGaA Details
2.9.2 Merck KGaA Major Business
2.9.3 Merck KGaA Immuno-Oncology Product and Solutions
2.9.4 Merck KGaA Immuno-Oncology Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.9.5 Merck KGaA Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Immuno-Oncology Revenue and Share by Players (2019, 2020, 2021, and 2022)
3.2 Market Concentration Rate
3.2.1 Top 3 Immuno-Oncology Players Market Share in 2021
3.2.2 Top 10 Immuno-Oncology Players Market Share in 2021
3.2.3 Market Competition Trend
3.3 Immuno-Oncology Players Head Office, Products and Services Provided
3.4 Immuno-Oncology Mergers & Acquisitions
3.5 Immuno-Oncology New Entrants and Expansion Plans
4 Market Size Segment by Type
4.1 Global Immuno-Oncology Revenue and Market Share by Type (2017-2022)
4.2 Global Immuno-Oncology Market Forecast by Type (2023-2028)
5 Market Size Segment by Application
5.1 Global Immuno-Oncology Revenue Market Share by Application (2017-2022)
5.2 Global Immuno-Oncology Market Forecast by Application (2023-2028)
6 North America by Country, by Type, and by Application
6.1 North America Immuno-Oncology Revenue by Type (2017-2028)
6.2 North America Immuno-Oncology Revenue by Application (2017-2028)
6.3 North America Immuno-Oncology Market Size by Country
6.3.1 North America Immuno-Oncology Revenue by Country (2017-2028)
6.3.2 United States Immuno-Oncology Market Size and Forecast (2017-2028)
6.3.3 Canada Immuno-Oncology Market Size and Forecast (2017-2028)
6.3.4 Mexico Immuno-Oncology Market Size and Forecast (2017-2028)
7 Europe by Country, by Type, and by Application
7.1 Europe Immuno-Oncology Revenue by Type (2017-2028)
7.2 Europe Immuno-Oncology Revenue by Application (2017-2028)
7.3 Europe Immuno-Oncology Market Size by Country
7.3.1 Europe Immuno-Oncology Revenue by Country (2017-2028)
7.3.2 Germany Immuno-Oncology Market Size and Forecast (2017-2028)
7.3.3 France Immuno-Oncology Market Size and Forecast (2017-2028)
7.3.4 United Kingdom Immuno-Oncology Market Size and Forecast (2017-2028)
7.3.5 Russia Immuno-Oncology Market Size and Forecast (2017-2028)
7.3.6 Italy Immuno-Oncology Market Size and Forecast (2017-2028)
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific Immuno-Oncology Revenue by Type (2017-2028)
8.2 Asia-Pacific Immuno-Oncology Revenue by Application (2017-2028)
8.3 Asia-Pacific Immuno-Oncology Market Size by Region
8.3.1 Asia-Pacific Immuno-Oncology Revenue by Region (2017-2028)
8.3.2 China Immuno-Oncology Market Size and Forecast (2017-2028)
8.3.3 Japan Immuno-Oncology Market Size and Forecast (2017-2028)
8.3.4 South Korea Immuno-Oncology Market Size and Forecast (2017-2028)
8.3.5 India Immuno-Oncology Market Size and Forecast (2017-2028)
8.3.6 Southeast Asia Immuno-Oncology Market Size and Forecast (2017-2028)
8.3.7 Australia Immuno-Oncology Market Size and Forecast (2017-2028)
9 South America by Country, by Type, and by Application
9.1 South America Immuno-Oncology Revenue by Type (2017-2028)
9.2 South America Immuno-Oncology Revenue by Application (2017-2028)
9.3 South America Immuno-Oncology Market Size by Country
9.3.1 South America Immuno-Oncology Revenue by Country (2017-2028)
9.3.2 Brazil Immuno-Oncology Market Size and Forecast (2017-2028)
9.3.3 Argentina Immuno-Oncology Market Size and Forecast (2017-2028)
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa Immuno-Oncology Revenue by Type (2017-2028)
10.2 Middle East & Africa Immuno-Oncology Revenue by Application (2017-2028)
10.3 Middle East & Africa Immuno-Oncology Market Size by Country
10.3.1 Middle East & Africa Immuno-Oncology Revenue by Country (2017-2028)
10.3.2 Turkey Immuno-Oncology Market Size and Forecast (2017-2028)
10.3.3 Saudi Arabia Immuno-Oncology Market Size and Forecast (2017-2028)
10.3.4 UAE Immuno-Oncology Market Size and Forecast (2017-2028)
11 Research Findings and Conclusion
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
List of TablesList of Tables
Table 1. Global Immuno-Oncology Revenue by Type, (USD Million), 2017 VS 2021 VS 2028
Table 2. Global Immuno-Oncology Revenue by Application, (USD Million), 2017 VS 2021 VS 2028
Table 3. Global Market Immuno-Oncology Revenue (Million USD) Comparison by Region (2017 VS 2021 VS 2028)
Table 4. Global Immuno-Oncology Revenue (USD Million) by Region (2017-2022)
Table 5. Global Immuno-Oncology Revenue Market Share by Region (2023-2028)
Table 6. Bristol-Myers Squibb Corporate Information, Head Office, and Major Competitors
Table 7. Bristol-Myers Squibb Major Business
Table 8. Bristol-Myers Squibb Immuno-Oncology Product and Solutions
Table 9. Bristol-Myers Squibb Immuno-Oncology Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 10. Merck & Co., Inc. Corporate Information, Head Office, and Major Competitors
Table 11. Merck & Co., Inc. Major Business
Table 12. Merck & Co., Inc. Immuno-Oncology Product and Solutions
Table 13. Merck & Co., Inc. Immuno-Oncology Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 14. Roche AG Corporate Information, Head Office, and Major Competitors
Table 15. Roche AG Major Business
Table 16. Roche AG Immuno-Oncology Product and Solutions
Table 17. Roche AG Immuno-Oncology Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 18. AstraZeneca, Plc Corporate Information, Head Office, and Major Competitors
Table 19. AstraZeneca, Plc Major Business
Table 20. AstraZeneca, Plc Immuno-Oncology Product and Solutions
Table 21. AstraZeneca, Plc Immuno-Oncology Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 22. Sanofi S.A. Corporate Information, Head Office, and Major Competitors
Table 23. Sanofi S.A. Major Business
Table 24. Sanofi S.A. Immuno-Oncology Product and Solutions
Table 25. Sanofi S.A. Immuno-Oncology Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 26. Dendreon Pharmaceuticals Corporate Information, Head Office, and Major Competitors
Table 27. Dendreon Pharmaceuticals Major Business
Table 28. Dendreon Pharmaceuticals Immuno-Oncology Product and Solutions
Table 29. Dendreon Pharmaceuticals Immuno-Oncology Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 30. Novartis Corporate Information, Head Office, and Major Competitors
Table 31. Novartis Major Business
Table 32. Novartis Immuno-Oncology Product and Solutions
Table 33. Novartis Immuno-Oncology Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 34. Gilead Sciences Inc. Corporate Information, Head Office, and Major Competitors
Table 35. Gilead Sciences Inc. Major Business
Table 36. Gilead Sciences Inc. Immuno-Oncology Product and Solutions
Table 37. Gilead Sciences Inc. Immuno-Oncology Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 38. Merck KGaA Corporate Information, Head Office, and Major Competitors
Table 39. Merck KGaA Major Business
Table 40. Merck KGaA Immuno-Oncology Product and Solutions
Table 41. Merck KGaA Immuno-Oncology Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 42. Global Immuno-Oncology Revenue (USD Million) by Players (2019, 2020, 2021, and 2022)
Table 43. Global Immuno-Oncology Revenue Share by Players (2019, 2020, 2021, and 2022)
Table 44. Breakdown of Immuno-Oncology by Company Type (Tier 1, Tier 2 and Tier 3)
Table 45. Immuno-Oncology Players Head Office, Products and Services Provided
Table 46. Immuno-Oncology Mergers & Acquisitions in the Past Five Years
Table 47. Immuno-Oncology New Entrants and Expansion Plans
Table 48. Global Immuno-Oncology Revenue (USD Million) by Type (2017-2022)
Table 49. Global Immuno-Oncology Revenue Share by Type (2017-2022)
Table 50. Global Immuno-Oncology Revenue Forecast by Type (2023-2028)
Table 51. Global Immuno-Oncology Revenue by Application (2017-2022)
Table 52. Global Immuno-Oncology Revenue Forecast by Application (2023-2028)
Table 53. North America Immuno-Oncology Revenue by Type (2017-2022) & (USD Million)
Table 54. North America Immuno-Oncology Revenue by Type (2023-2028) & (USD Million)
Table 55. North America Immuno-Oncology Revenue by Application (2017-2022) & (USD Million)
Table 56. North America Immuno-Oncology Revenue by Application (2023-2028) & (USD Million)
Table 57. North America Immuno-Oncology Revenue by Country (2017-2022) & (USD Million)
Table 58. North America Immuno-Oncology Revenue by Country (2023-2028) & (USD Million)
Table 59. Europe Immuno-Oncology Revenue by Type (2017-2022) & (USD Million)
Table 60. Europe Immuno-Oncology Revenue by Type (2023-2028) & (USD Million)
Table 61. Europe Immuno-Oncology Revenue by Application (2017-2022) & (USD Million)
Table 62. Europe Immuno-Oncology Revenue by Application (2023-2028) & (USD Million)
Table 63. Europe Immuno-Oncology Revenue by Country (2017-2022) & (USD Million)
Table 64. Europe Immuno-Oncology Revenue by Country (2023-2028) & (USD Million)
Table 65. Asia-Pacific Immuno-Oncology Revenue by Type (2017-2022) & (USD Million)
Table 66. Asia-Pacific Immuno-Oncology Revenue by Type (2023-2028) & (USD Million)
Table 67. Asia-Pacific Immuno-Oncology Revenue by Application (2017-2022) & (USD Million)
Table 68. Asia-Pacific Immuno-Oncology Revenue by Application (2023-2028) & (USD Million)
Table 69. Asia-Pacific Immuno-Oncology Revenue by Region (2017-2022) & (USD Million)
Table 70. Asia-Pacific Immuno-Oncology Revenue by Region (2023-2028) & (USD Million)
Table 71. South America Immuno-Oncology Revenue by Type (2017-2022) & (USD Million)
Table 72. South America Immuno-Oncology Revenue by Type (2023-2028) & (USD Million)
Table 73. South America Immuno-Oncology Revenue by Application (2017-2022) & (USD Million)
Table 74. South America Immuno-Oncology Revenue by Application (2023-2028) & (USD Million)
Table 75. South America Immuno-Oncology Revenue by Country (2017-2022) & (USD Million)
Table 76. South America Immuno-Oncology Revenue by Country (2023-2028) & (USD Million)
Table 77. Middle East & Africa Immuno-Oncology Revenue by Type (2017-2022) & (USD Million)
Table 78. Middle East & Africa Immuno-Oncology Revenue by Type (2023-2028) & (USD Million)
Table 79. Middle East & Africa Immuno-Oncology Revenue by Application (2017-2022) & (USD Million)
Table 80. Middle East & Africa Immuno-Oncology Revenue by Application (2023-2028) & (USD Million)
Table 81. Middle East & Africa Immuno-Oncology Revenue by Country (2017-2022) & (USD Million)
Table 82. Middle East & Africa Immuno-Oncology Revenue by Country (2023-2028) & (USD Million)
List of Figures
Figure 1. Immuno-Oncology Picture
Figure 2. Global Immuno-Oncology Revenue Market Share by Type in 2021
Figure 3. Immune Checkpoint Inhibitors
Figure 4. Cytokine-Based Immunotherapy
Figure 5. Cancer Vaccines
Figure 6. CAR-T Cell Therapy
Figure 7. Others
Figure 8. Immuno-Oncology Revenue Market Share by Application in 2021
Figure 9. Hospitals Picture
Figure 10. Drugstores Picture
Figure 11. Others Picture
Figure 12. Global Immuno-Oncology Market Size, (USD Million): 2017 VS 2021 VS 2028
Figure 13. Global Immuno-Oncology Revenue and Forecast (2017-2028) & (USD Million)
Figure 14. Global Immuno-Oncology Revenue Market Share by Region (2017-2028)
Figure 15. Global Immuno-Oncology Revenue Market Share by Region in 2021
Figure 16. North America Immuno-Oncology Revenue (USD Million) and Growth Rate (2017-2028)
Figure 17. Europe Immuno-Oncology Revenue (USD Million) and Growth Rate (2017-2028)
Figure 18. Asia-Pacific Immuno-Oncology Revenue (USD Million) and Growth Rate (2017-2028)
Figure 19. South America Immuno-Oncology Revenue (USD Million) and Growth Rate (2017-2028)
Figure 20. Middle East and Africa Immuno-Oncology Revenue (USD Million) and Growth Rate (2017-2028)
Figure 21. Immuno-Oncology Market Drivers
Figure 22. Immuno-Oncology Market Restraints
Figure 23. Immuno-Oncology Market Trends
Figure 24. Bristol-Myers Squibb Recent Developments and Future Plans
Figure 25. Merck & Co., Inc. Recent Developments and Future Plans
Figure 26. Roche AG Recent Developments and Future Plans
Figure 27. AstraZeneca, Plc Recent Developments and Future Plans
Figure 28. Sanofi S.A. Recent Developments and Future Plans
Figure 29. Dendreon Pharmaceuticals Recent Developments and Future Plans
Figure 30. Novartis Recent Developments and Future Plans
Figure 31. Gilead Sciences Inc. Recent Developments and Future Plans
Figure 32. Merck KGaA Recent Developments and Future Plans
Figure 33. Global Immuno-Oncology Revenue Share by Players in 2021
Figure 34. Immuno-Oncology Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2021
Figure 35. Global Top 3 Players Immuno-Oncology Revenue Market Share in 2021
Figure 36. Global Top 10 Players Immuno-Oncology Revenue Market Share in 2021
Figure 37. Key Players Market Share Trend (Top 3 Market Share: 2020 VS 2021 VS 2022)
Figure 38. Global Immuno-Oncology Revenue Share by Type in 2021
Figure 39. Global Immuno-Oncology Market Share Forecast by Type (2023-2028)
Figure 40. Global Immuno-Oncology Revenue Share by Application in 2021
Figure 41. Global Immuno-Oncology Market Share Forecast by Application (2023-2028)
Figure 42. North America Immuno-Oncology Sales Market Share by Type (2017-2028)
Figure 43. North America Immuno-Oncology Sales Market Share by Application (2017-2028)
Figure 44. North America Immuno-Oncology Revenue Market Share by Country (2017-2028)
Figure 45. United States Immuno-Oncology Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 46. Canada Immuno-Oncology Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 47. Mexico Immuno-Oncology Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 48. Europe Immuno-Oncology Sales Market Share by Type (2017-2028)
Figure 49. Europe Immuno-Oncology Sales Market Share by Application (2017-2028)
Figure 50. Europe Immuno-Oncology Revenue Market Share by Country (2017-2028)
Figure 51. Germany Immuno-Oncology Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 52. France Immuno-Oncology Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 53. United Kingdom Immuno-Oncology Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 54. Russia Immuno-Oncology Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 55. Italy Immuno-Oncology Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 56. Asia-Pacific Immuno-Oncology Sales Market Share by Type (2017-2028)
Figure 57. Asia-Pacific Immuno-Oncology Sales Market Share by Application (2017-2028)
Figure 58. Asia-Pacific Immuno-Oncology Revenue Market Share by Region (2017-2028)
Figure 59. China Immuno-Oncology Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 60. Japan Immuno-Oncology Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 61. South Korea Immuno-Oncology Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 62. India Immuno-Oncology Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 63. Southeast Asia Immuno-Oncology Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 64. Australia Immuno-Oncology Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 65. South America Immuno-Oncology Sales Market Share by Type (2017-2028)
Figure 66. South America Immuno-Oncology Sales Market Share by Application (2017-2028)
Figure 67. South America Immuno-Oncology Revenue Market Share by Country (2017-2028)
Figure 68. Brazil Immuno-Oncology Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 69. Argentina Immuno-Oncology Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 70. Middle East and Africa Immuno-Oncology Sales Market Share by Type (2017-2028)
Figure 71. Middle East and Africa Immuno-Oncology Sales Market Share by Application (2017-2028)
Figure 72. Middle East and Africa Immuno-Oncology Revenue Market Share by Country (2017-2028)
Figure 73. Turkey Immuno-Oncology Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 74. Saudi Arabia Immuno-Oncology Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 75. UAE Immuno-Oncology Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 76. Methodology
Figure 77. Research Process and Data Source
Published By : GlobalInfoResearch
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
